Dr. Benedito Carneiro
Claim this profileLifespan Cancer Institute
Studies Solid Tumors
Studies Cystic Tumor
11 reported clinical trials
21 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
NTRK1 positive
2Cystic Tumor
Stage IV
Stage III
NTRK1 positive
Affiliated Hospitals
Clinical Trials Benedito Carneiro is currently running
DF6215
for Solid Tumors
This trial tests a modified protein that helps the immune system fight cancer in patients with solid tumors by making it easier for immune cells to find and destroy cancer cells.
Recruiting1 award Phase 110 criteria
TY-2136b
for Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.
Recruiting1 award Phase 1
More about Benedito Carneiro
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Benedito Carneiro has experience with
- TY-2136b
- Palbociclib Oral Product
- TAS-116
- Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
- Programmed Cell Death-1 (PD-1) Inhibitor
- ABBV-CLS-484
Breakdown of trials Benedito Carneiro has run
Solid Tumors
Cystic Tumor
Cancer
Breast Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Benedito Carneiro specialize in?
Is Benedito Carneiro currently recruiting for clinical trials?
Are there any treatments that Benedito Carneiro has studied deeply?
What is the best way to schedule an appointment with Benedito Carneiro?
What is the office address of Benedito Carneiro?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.